MetaCap

Guardant Health (GH) vs Revvity (RVTY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

Guardant Health (GH) has outperformed Revvity (RVTY) over the past year, gaining 153.5% versus a gain of 65.8%. Over five years, GH leads with a +63.0% price change compared with -10.4% for RVTY. Guardant Health is the larger company by market cap ($22.79 billion vs $17.09 billion), about 1.3 times the size.

Revvity pays a dividend yielding 0.18%, while Guardant Health does not currently pay one. Revvity converts more of its revenue into profit, with a net margin of 8.4% versus -42.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GH+153.46%RVTY+65.81%
+196%+88%-20%
Oct 8, 20251 yearOct 8, 2026
GH+58.69%RVTY-10.48%
+80%-6%-92%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GH versus RVTY key metrics
MetricGHRVTY
Share price$169.85$153.15
Market cap$22.79B$17.09B
1-day change+2.59%+0.71%
YTD return+62.09%+57.27%
1-year return+153.46%+65.81%
5-year return+62.95%-10.40%
P/E ratio (TTM)—73.28
Forward P/E—25.98
EPS (TTM)$-3.50$2.09
Dividend yield0.00%0.18%
Annual dividend$0.00$0.28
Revenue (latest FY)$982.02M$2.86B
Revenue growth (YoY)+32.88%+3.67%
Net income (latest FY)$-416.28M$241.20M
Gross margin64.46%—
Operating margin-44.53%12.49%
Net margin-42.39%8.45%
52-week high$191.05$166.25
52-week low$61.00$81.22
Distance from 52-week high-11.10%-7.88%
Analyst consensusstrong_buybuy
Avg. price target upside+17.66%-11.28%
Average volume1.98M1.79M
Shares outstanding134.20M111.59M
Employees2,49011,000
SectorHealth CareIndustrials
IndustryMedical SpecialitiesBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GH has outperformed RVTY by 87.7 percentage points over the past year.
  • Revvity is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -42.4 cents for Guardant Health.
  • Guardant Health grew revenue faster in its latest fiscal year (+32.88% vs +3.67%).
  • The two companies sit in different sectors: Guardant Health in Health Care and Revvity in Industrials.

About Guardant Health

GH stock →

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights.

Health Care · Medical Specialities · 2,490 employees

About Revvity

RVTY stock →

Revvity, Inc. provides health sciences solutions, technologies, and services.

Industrials · Biotechnology: Laboratory Analytical Instruments · 11,000 employees

GH vs RVTY FAQ

Which is bigger, Guardant Health or Revvity?

Guardant Health (GH) is larger, with a market capitalization of $22.79B compared with $17.09B for Revvity (RVTY).

Which stock has performed better over the past year, GH or RVTY?

GH returned +153.46% over the past 12 months, compared with +65.81% for RVTY (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Guardant Health or Revvity?

Revvity pays a dividend yielding 0.18%, while Guardant Health does not currently pay a regular dividend.

Are Guardant Health and Revvity in the same industry?

No. Guardant Health is in the Health Care sector, while Revvity is in Industrials.

More comparisons